# AZD0486

Source: https://onco.cc/drugs/azd0486/  
OnCo record `azd0486` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AZD0486 is an experimental bispecific antibody from AstraZeneca in phase 3 trials for diffuse large B-cell lymphoma, aimed at CD19 and CD3.

## Summary

AZD0486 (TNB-486) is a bispecific antibody developed by AstraZeneca. Its targets are CD19 and CD3 (the sponsor names CD19 x CD3). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07215585 (AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL), in diffuse large B-cell lymphoma. The largest, NCT07215585, plans to enrol 420 participants with primary completion expected 2030-06-10. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: TNB-486
- Modality: bispecific antibody
- Mechanism: Bispecific antibody directed at CD19 and CD3, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov: trials of AZD0486: https://clinicaltrials.gov/search?intr=TNB-486

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- targets: [CD19](https://onco.cc/targets/cd19/), [CD3](https://onco.cc/targets/cd3/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- trials: [A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies](https://onco.cc/trials/nct06564038/), [A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients](https://onco.cc/trials/nct06549595/), [AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL](https://onco.cc/trials/nct07215585/), [Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL](https://onco.cc/trials/nct06526793/), [Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin He](https://onco.cc/trials/nct07509151/)

---
JSON: https://onco.cc/api/v1/entities/azd0486.json